| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 68001-0651-37 | 68001-0651 | Paclitaxel | Paclitaxel protein-bound particles for injectable suspension (albumin-bound) | 100.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jul 18, 2025 | In Use | |
| 68001-0652-17 | 68001-0652 | ISOTRETINOIN | ZENATANE | 10.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Jul 11, 2025 | In Use | |
| 68001-0653-17 | 68001-0653 | ISOTRETINOIN | ZENATANE | 20.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Jul 11, 2025 | In Use | |
| 68001-0654-17 | 68001-0654 | ISOTRETINOIN | ZENATANE | 30.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Jul 11, 2025 | In Use | |
| 68001-0655-17 | 68001-0655 | ISOTRETINOIN | ZENATANE | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Jul 11, 2025 | In Use | |
| 68001-0656-41 | 68001-0656 | Eribulin Mesylate | Eribulin Mesylate | 0.5 mg/mL | Chemotherapy | Antimitotic Agent | Furopyrans | Intravenous | Sep 15, 2025 | In Use | |
| 68001-0662-06 | 68001-0662 | Dasatinib | Dasatinib | 70.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 29, 2025 | In Use | |
| 68001-0663-04 | 68001-0663 | Dasatinib | Dasatinib | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 29, 2025 | In Use | |
| 68001-0664-04 | 68001-0664 | Dasatinib | Dasatinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 29, 2025 | In Use | |
| 68001-0665-04 | 68001-0665 | Dasatinib | Dasatinib | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 29, 2025 | In Use | |
| 68001-0666-01 | 68001-0666 | Aprepitant | Aprepitant | 40.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Dec 1, 2025 | In Use | |
| 68001-0666-17 | 68001-0666 | Aprepitant | Aprepitant | 40.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Dec 1, 2025 | In Use | |
| 68001-0667-01 | 68001-0667 | Aprepitant | Aprepitant | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Dec 1, 2025 | In Use | |
| 68001-0667-19 | 68001-0667 | Aprepitant | Aprepitant | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Dec 1, 2025 | In Use | |
| 68001-0668-19 | 68001-0668 | Aprepitant | Aprepitant | 125.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Dec 1, 2025 | In Use | |
| 68001-0669-15 | 68001-0669 | Aprepitant | Aprepitant | 80.0 mg/1, 125.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Dec 1, 2025 | In Use | |
| 68001-0673-06 | 68001-0673 | Abiraterone Acetate | Abiraterone | 500.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Sep 1, 2025 | In Use | |
| 68001-0681-25 | 68001-0681 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Dec 1, 2025 | In Use | |
| 68001-0682-26 | 68001-0682 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Dec 1, 2025 | In Use | |
| 68001-0683-27 | 68001-0683 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Dec 1, 2025 | In Use | |
| 68047-0702-01 | 68047-0702 | Dexamethasone 1.5 mg | Dexamethasone | 1.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sep 1, 2017 | In Use | |
| 68047-0702-21 | 68047-0702 | Dexamethasone 1.5 mg | Dexamethasone | 1.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 8, 2018 | In Use | |
| 68047-0702-35 | 68047-0702 | Dexamethasone 1.5 mg | Dexamethasone | 1.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 8, 2018 | In Use | |
| 68047-0702-51 | 68047-0702 | Dexamethasone 1.5 mg | Dexamethasone | 1.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 8, 2018 | In Use | |
| 68071-1547-01 | 68071-1547 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 26, 2017 | Dec 31, 2019 | In Use |
Found 12159 results — Export these results
Home